GLP1R and COVID-19: Consequently, while the potential benefits of GLP‐1 receptor agonists in mitigating the severity of COVID‐19 are intriguing, clinicians must exercise caution and carefully weigh the potential risks, particularly in patients with a predisposition to gatrointestinal issues and renal complications.